Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Risankizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody developed and approved for the treatment of moderate-to-severe plaque psoriasis at a dose of 150 mg administered subcutaneously at weeks 0 and 4, and every 12 weeks thereafter. Ongoing trials are investigating the use of risankizumab in other inflammatory autoimmune diseases. Ri...
Alternative Titles
Full title
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7051925
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7051925
Other Identifiers
ISSN
0312-5963
E-ISSN
1179-1926
DOI
10.1007/s40262-019-00842-5
